The safety and effectiveness of Afinitor there is no guarantee in oncology and there is no guarantee that Afinitor will be commercially available for oncology indications. The active ingredient in Afinitor is everolimus, which is available in various dosages under the trade name Certica for the prevention of organ rejection in heart and kidney transplant recipients generic cymbalta . Certican was first approved in the EU in 2003.
About NovartisNovartis AG provides healthcare solutions the evolving the evolving needs of patients and societies. Cost-company exclusively exclusively on the health sector and offers a diversified portfolio to best meet these needs: innovative medicines, cost – saving generic pharmaceuticals, preventive vaccines, diagnostic and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the the Group continuing operations of USD 38.1 billion of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 in R & D in R & D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employing approximately 97,000 full-time associates and operate in over 140 countries employ over the world. For further information, please visit.
Over Viroblock SA – being Viroblock SA is a Swiss startup -up founded in 2005, gelding pioneers pioneer and the world leader in blocking viral transmission technology.